The Ministry of Health, Labor and Welfare (MHLW) on December 10 officially revealed the overview of its distribution and storage plans in Japan for three frontrunner COVID-19 vaccines being developed by Pfizer, Moderna, and AstraZeneca, along with their characteristics known…
To read the full story
Related Article
- MHLW Says 7,500 Vaccine Freezers for Storage at Minus 20 Degrees C, Presumably for Moderna Shot
November 30, 2020
- MHLW Scrambling to Set Up Vaccination System for Ultracold-Chain Required COVID-19 Vaccine
November 26, 2020
- MHLW to Prepare 7,500 More Freezers for COVID-19 Vaccine Storage at Medical Institutions
November 25, 2020
- MHLW Expects Use of Dry Ice-Fitted Cooling Boxes to Deliver Ultracold Chain-Required COVID-19 Shots: Official
November 19, 2020
REGULATORY
- MHLW Panel Deems 4 More “Drug Loss” Products as High-Need
May 27, 2026
- LDP Panel OKs Immunization Act Bill Aimed at Beyfortus NIP Use
May 27, 2026
- Japan Selects JN.1 Substrains for COVID Vaccines in 2026-2027 Season
May 27, 2026
- Ex-Minister Kato Preparing Parliamentary Group on Diabetes Issues
May 27, 2026
- LDP Lawmakers’ League Urges Economic Efficiency in Drug Use
May 27, 2026
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…





